Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06109441 · ClinicalTrials.gov registry record · Phase 2
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
A Phase 2 study of Ulcerative Colitis, sponsored by AltruBio.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06109441 is a Phase 2 study of Ulcerative Colitis that is active but no longer recruiting, run by AltruBio. The registered enrollment target is 50 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06109441, a Phase 2 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by AltruBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
Conditions Studied
Interventions
- BIOLOGICAL ALTB-268
Study Locations (20)
Texas
- DHAT / GI Aliance - Garland
- Caprock Gastro Reasearch - Lubbock
- GI Alliance - Mansfield
- Southern Star Research Institute LLC - San Antonio
Florida
- Gastro Health Research - Miami
- Digestive and Liver Center of Florida, LLC - Orlando
- Alliance Clinical Research of Tampa, LLC. - Tampa
New York
- New York Presbyterian Hospital - Weill Cornell Medical Colllege - New York
- Gastroenterology Group of Rochester - Rochester
- Digestive Disease Medicine of Central New York - Utica
Ohio
- Dayton Gastroenterology, LLC - Beavercreek
- Gastro Health Ohio - Liberty Township
California
- San Diego Gastroenterology - San Diego
Colorado
- Rocky Mountain Gastroenterology - Littleton
Indiana
- Gastro Health Partners Southern Indiana - New Albany
Kentucky
- Gastro Health Partners Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06109441
The ClinicalTrials.gov registry entry for NCT06109441 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is AltruBio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which ALTB-268 is the first listed.
NCT06109441 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06109441 about?
NCT06109441 is a clinical study titled "Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics". ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
What is the current status of trial NCT06109441?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-12-04. Estimated completion is 2027-03.
What conditions does trial NCT06109441 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06109441?
The interventions under investigation include: ALTB-268 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06109441?
This trial is sponsored by AltruBio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06109441 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.